Pharmos(PARS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS)

PARS 2.700

+13.6%

Jan 21 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Stephen D. Wilson who wrote (560)	4/6/1998 6:50:00 PM
From: Kirsten	Read Replies (1) of 1491

Stephen -- I saw the Reuters article as well as the upgrade from Furman Selz which cited the NCI study as the reason for the upgrade. Don't know much about Evista other than LLY just put it on the market, that risk of uterine cancer is not a side effect (wasn't there some controversy surrounding that claim??), and that it hasn't been selling as well as anticipated. I know that the PARS derivative will also attempt to reduce side effects, but why will it be a better product than Evista? Found a little info on the pharmos website but not enough to make a comparison... Kirsten

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next